Advertisement Takeda Phase III trial of VEDOLIZUMAB meets primary endpoints - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Takeda Phase III trial of VEDOLIZUMAB meets primary endpoints

Takeda Pharmaceutical has announced positive results from Pivotal Phase III trial of VEDOLIZUMAB in patients with moderately to severely active ulcerative colitis who have failed at least one conventional therapy.

The randomized, placebo-controlled GEMINI I trial has met primary endpoints of improvements in clinical response in induction and clinical remission in maintenance.

In the double-blinded trial, patients were given vedolizumab (MLN0002) or placebo treatment for a year, starting with six weeks of induction therapy.

The most common adverse events (more than 10%) such as colitis, headache and nasopharyngitis were observed in both the vedolizumab arm and the placebo arm.

Takeda chief medical and scientific officer Tadataka Yamada said they are very pleased with the outcomes of this pivotal trial, and the potential that vedolizumab holds for patients with this debilitating disease.